1. Clinical & Scientific Overview
Lamotrigine & Topiramate (TIP-MED-000232, Reference Code [11.28]) is classified under
Neurology & Antiepileptic Medicines (Ch 11) as a Broad-Spectrum Antiepileptics, Bipolar Mood Stabiliser & Migraine Prophylaxis.
Within the Indian regulatory and compendial framework, it is governed under Schedule H Prescription Drug (To be sold by retail on the prescription of a Registered Medical Practitioner only — Drugs Rules 1945).
Representative Indian Market Examples (Edition 2.7 Ch 11 [11.28], p. 153): Lamotrigine: Lamitor-DT (Torrent — 25 mg, 50 mg, 100 mg), Lamez (Intas), Lametec (Cipla); Topiramate: Topamac (Janssen — 25 mg, 50 mg, 100 mg), Topaz (Intas), Epitop (Sun) — Strengths & Dosage Forms: Lamotrigine Dispersible/Oral Tablets: 25 mg, 50 mg, 100 mg, 200 mg. Topiramate Film-Coated Tablets / Sprinkle Capsules: 25 mg, 50 mg, 100 mg.
Lamotrigine Dispersible/Oral Tablets: 25 mg, 50 mg, 100 mg, 200 mg. Topiramate Film-Coated Tablets / Sprinkle Capsules: 25 mg, 50 mg, 100 mg.
3. Mechanism of Action & Pharmacodynamics
Lamotrigine blocks voltage-gated Na+ channels and inhibits presynaptic glutamate release; Topiramate blocks Na+ channels, potentiates GABA-A, blocks AMPA/kainate, and weakly inhibits carbonic anhydrase.
4. Therapeutic Indications & Evidence-Supported Uses
- Focal & generalised epilepsy, Lennox–Gastaut syndrome, Bipolar I depressive maintenance (Lamotrigine — preferred in women of childbearing age over Valproate), and chronic migraine prophylaxis (Topiramate 50–100 mg/day)
🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: Lamotrigine (CRITICAL VALPROATE INTERACTION): Alone: 25 mg OD x 2 wk, 50 mg OD x 2 wk, then 100–200 mg/day. With Valproate (halve dose!): 25 mg ALTERNATE DAYS x 2 wk, then 25 mg OD x 2 wk, target 100–200 mg/day. Topiramate: Start 25 mg bedtime x 1 wk; titrate to 50 mg BD.
Administration & Meal Timing: With or without food; maintain high daily water intake (>=2–2.5 L/day) with Topiramate to prevent calcium phosphate kidney stones. | Once daily at bedtime (initial titration) or BD maintenance.
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
Renal: Halve Topiramate dose if CrCl <70 mL/min. Hepatic: Reduce Lamotrigine dose by 50% in Child-Pugh B and 75% in Child-Pugh C.
Renal: Halve Topiramate dose if CrCl <70 mL/min. Hepatic: Reduce Lamotrigine dose by 50% in Child-Pugh B and 75% in Child-Pugh C.
Renal: Halve Topiramate dose if CrCl <70 mL/min. Hepatic: Reduce Lamotrigine dose by 50% in Child-Pugh B and 75% in Child-Pugh C.
7. Contraindications, Precautions & High-Risk Warnings
- LAMOTRIGINE LIFE-THREATENING SJS/TEN RASH & TOPIRAMATE ANGLE-CLOSURE GLAUCOMA / ACIDOSIS: Rapid titration of Lamotrigine (or failing to halve dose with Valproate) causes fatal Stevens–Johnson Syndrome / TEN (1% paediatric, 0.3% adult). Topiramate causes acute bilateral secondary angle-closure glaucoma, oligohidrosis (paediatric heatstroke), metabolic acidosis, and cleft lip teratogenicity.
Key Clinical Precautions: Renal: Halve Topiramate dose if CrCl <70 mL/min. Hepatic: Reduce Lamotrigine dose by 50% in Child-Pugh B and 75% in Child-Pugh C.
8. Adverse Effects Profile
- Lamotrigine: Benign rash (10%), dizziness, diplopia, insomnia. Topiramate: Paraesthesia (tingling fingers/toes), weight loss/anorexia, 'word-finding' cognitive slowing, nephrolithiasis.
- Stevens–Johnson Syndrome / TEN & DRESS (Lamotrigine — Weeks 2–8), acute myopia with secondary angle-closure glaucoma (Topiramate — within 1 month), hyperchloraemic metabolic acidosis, nephrolithiasis.
- Monitor for severe hypersensitivity, organ toxicity, or dose-limiting adverse events.
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- Valproate potently inhibits UGT1A4 glucuronidation, DOUBLING Lamotrigine half-life to ~60h (mandatory 50% dose reduction!)
- Carbamazepine, Phenytoin, Phenobarbitone & Ethinylestradiol OCPs double Lamotrigine clearance
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.
Pharmacist Patient Counselling Points:
- Patient Counselling Checklist: STOP Lamotrigine and seek immediate medical care at the first sign of ANY skin rash, fever, or mouth ulcers; if you miss Lamotrigine for >5 days, do NOT resume your full dose; with Topiramate, drink 8–10 glasses of water daily and report sudden eye pain/blurred vision immediately.
- Meal & Clock Timing Instruction: With or without food; maintain high daily water intake (>=2–2.5 L/day) with Topiramate to prevent calcium phosphate kidney stones. (Once daily at bedtime (initial titration) or BD maintenance.)
- Missed Dose Protocol: Take as soon as remembered unless close to next scheduled dose; never double the dose.
- Geriatric Dispensing Pearl: Schedule: Schedule H | NLEM 2022: Yes (Lamotrigine) | Compendia: NFI 7th Ed 2026 / NLEM 2022 / ILAE Guidelines
Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Lamotrigine Dispersible/Oral Tablets: 25 mg, 50 mg, 100 mg, 200 mg. Topiramate Film-Coated Tablets / Sprinkle Capsules: 25 mg, 50 mg, 100 mg.
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: Indian Pharmacist Desk Reference — Professional Edition 2.7 (2026–27) • Ch 11 [11.28] (p. 153)
Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: HANDBOOK_SOURCE_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.
13. Related Reference Monographs, Educational Guides & Visual Concept
💊 Related Pharmacological / Category Profiles
- [11.9] Levetiracetam — Second-Generation Pyrrolidone Antiepileptic (Binds Synaptic Vesic
- [11.10] Carbamazepine (and Oxcarbazepine comparison) — Iminostilbene Voltage-Gated Sodium Channel Blocker (Antiepileptic
- [11.11] Donepezil Hydrochloride — Centrally Acting Reversible Acetylcholinesterase Inhibitor (AChEI
- [11.12] Memantine Hydrochloride — Low-to-Moderate Affinity, Voltage-Dependent, Uncompetitive NMDA (
